Scarica l'app Stockscreener
6.05
2.73%
-0.17
Dopo l'orario di chiusura:
5.75
-0.30
-4.96%
Precedente Chiudi:
$6.22
Aprire:
$5.95
Volume 24 ore:
1.47M
Relative Volume:
0.79
Capitalizzazione di mercato:
$584.93M
Reddito:
-
Utile/perdita netta:
$-29.07M
Rapporto P/E:
-20.86
EPS:
-0.29
Flusso di cassa netto:
$-31.85M
1 W Prestazione:
-6.92%
1M Prestazione:
+36.26%
6M Prestazione:
+100.33%
1 anno Prestazione:
+94.85%
Intervallo 1D:
$5.78
$6.105
Intervallo di 1 settimana:
$5.6501
$6.50
Portata 52W:
$2.30
$7.39
Trevi Therapeutics Inc Stock (TRVI) Company Profile
Nome
Trevi Therapeutics Inc
Settore
Industria
Telefono
203-304-2499
Indirizzo
195 CHURCH STREET, NEW HAVEN, CT
Confronta TRVI con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TRVI
Trevi Therapeutics Inc
|
6.05 | 584.93M | 0 | -29.07M | -31.85M | -0.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Trevi Therapeutics Inc Stock (TRVI) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-10 | Reiterato | Needham | Buy |
| 2025-03-10 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2024-12-12 | Reiterato | H.C. Wainwright | Buy |
| 2024-09-09 | Ripresa | Leerink Partners | Outperform |
| 2024-08-30 | Iniziato | H.C. Wainwright | Buy |
| 2024-08-30 | Iniziato | Raymond James | Outperform |
| 2024-06-13 | Iniziato | Rodman & Renshaw | Buy |
| 2023-04-12 | Iniziato | B. Riley Securities | Buy |
| 2022-11-22 | Iniziato | SVB Leerink | Outperform |
| 2019-06-03 | Iniziato | BMO Capital Markets | Outperform |
| 2019-06-03 | Iniziato | Needham | Buy |
| 2019-06-03 | Iniziato | SVB Leerink | Outperform |
| 2019-06-03 | Iniziato | Stifel | Buy |
Mostra tutto
Trevi Therapeutics Inc Borsa (TRVI) Ultime notizie
Prurigo Nodularis Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Celgene Crp., Novartis, Pfizer, Galderma, Genentech, Incyte Crp., Trevi Therapeutics, Vyne Therapeutics - The Globe and Mail
Trevi's Game-Changing Chronic Cough Treatment Takes Center Stage at 3 Major Healthcare Conferences - Stock Titan
Trevi Therapeutics to Participate in Upcoming April Investor Conferences - Longview News-Journal
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Sees Significant Growth in Short Interest - Defense World
Charles Schwab Investment Management Inc. Has $713,000 Stock Holdings in Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World
Trevi Therapeutics advances cough treatment pipeline, eyes key clinical milestones - Proactive financial news
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Shares Acquired by Bank of New York Mellon Corp - Defense World
Trevi therapeutics chief scientific officer Sciascia sells $17,364 in stock - Investing.com
Trevi therapeutics CEO Jennifer Good sells $34,624 in stock By Investing.com - Investing.com South Africa
Trevi therapeutics CEO Jennifer Good sells $34,624 in stock - Investing.com
Leerink Partnrs Has Optimistic Outlook of TRVI Q1 Earnings - MarketBeat
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Q4 2024 Earnings Call Transcript - Insider Monkey
Q3 EPS Estimate for Trevi Therapeutics Reduced by Analyst - Defense World
Equities Analysts Offer Predictions for TRVI Q2 Earnings - Defense World
Leerink Partnrs Analysts Boost Earnings Estimates for TRVI - Defense World
HC Wainwright Reiterates “Buy” Rating for Trevi Therapeutics (NASDAQ:TRVI) - Defense World
Trevi Therapeutics (NASDAQ:TRVI) Earns “Buy” Rating from B. Riley - Defense World
D. Boral Capital Reaffirms Buy Rating for Trevi Therapeutics (NASDAQ:TRVI) - Defense World
Invesco Canada announces cash distributions for its ETFs - The Globe and Mail
Needham & Company LLC Lowers Trevi Therapeutics (NASDAQ:TRVI) Price Target to $24.00 - Defense World
Brokerages Set Trevi Therapeutics, Inc. (NASDAQ:TRVI) Price Target at $15.94 - Defense World
Trevi Therapeutics (NASDAQ:TRVI) Shares Gap Up Following Better-Than-Expected Earnings - Defense World
Trevi Therapeutics Stock (TRVI) Surges Over 60% on Promising Trial Results and Q4 Financials - Markets Insider
B. Riley Boosts Price Target on Trevi Therapeutics to $20 From $11, Keeps Buy Rating - Marketscreener.com
Trevi Therapeutics Inc (TRVI) Q4 2024 Earnings Call Highlights: Navigating Losses and Advancing ... - Yahoo
Trevi Therapeutics Inc (TRVI) Q4 2024 Earnings Call Highlights: Navigating Losses and Advancing Promising Trials - GuruFocus
Trevi Therapeutics Advances Haduvio in Clinical Trials - TipRanks
Earnings call transcript: Trevi Therapeutics Q4 2024 reports mixed results - Investing.com
Trevi Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Trevi Therapeutics Reports Fourth Quarter and Year End 2024 Financial Results and Provides Business Updates - PR Newswire
TRVI Stock Soars on Meeting Primary Goal in Chronic Cough Study - MSN
Trevi Therapeutics, Inc.'s (NASDAQ:TRVI) large institutional owners must be happy as stock continues to impress, up 57% over the past week - Yahoo Finance
Trevi Therapeutics Inc expected to post a loss of 12 cents a shareEarnings Preview - TradingView
HC Wainwright Analysts Increase Earnings Estimates for TRVI - Defense World
Stock Traders Purchase Large Volume of Trevi Therapeutics Call Options (NASDAQ:TRVI) - The AM Reporter
Trevi Therapeutics’ chief commercial officer sells $548,877 in stock - Investing.com India
Trevi Therapeutics’ chief commercial officer sells $548,877 in stock By Investing.com - Investing.com South Africa
Biotech Alert: Searches spiking for these stocks today - TipRanks
Investors Buy High Volume of Trevi Therapeutics Call Options (NASDAQ:TRVI) - Defense World
Trevi Therapeutics (NASDAQ:TRVI) Price Target Raised to $20.00 at Oppenheimer - Defense World
Trevi Therapeutics (NASDAQ:TRVI) Hits New 52-Week High After Analyst Upgrade - Defense World
Trevi Therapeutics (TRVI) Projected to Post Quarterly Earnings on Wednesday - Defense World
Trevi Therapeutics to Report Fourth Quarter and Year End 2024 Financial Results and Provide a Corporate Update on March 18, 2025 - The Malaysian Reserve
Trevi Therapeutics price target raised to $20 from $12 at Oppenheimer - TipRanks
Trevi Therapeutics (NASDAQ:TRVI) Receives Buy Rating from D. Boral Capital - MarketBeat
Trevi Therapeutics to Report Fourth Quarter and Year End 2024 Financial Results and Provide a Corporate Update on March 18, 2025 – Company AnnouncementFT.com - Financial Times
Trevi Therapeutics (NASDAQ:TRVI) Upgraded to Strong-Buy at Raymond James - Defense World
Needham & Company LLC Issues Positive Forecast for Trevi Therapeutics (NASDAQ:TRVI) Stock Price - Defense World
Trevi Therapeutics to Participate in Upcoming March Investor Conferences - Kilgore News Herald
Trevi Therapeutics stock soars to 52-week high of $6.58 By Investing.com - Investing.com Australia
Trevi Therapeutics reports positive Phase 2a trial results - Investing.com India
Trevi Therapeutics Inc Azioni (TRVI) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.01%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):